Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: A secondary analysis of the Phase III CREST trial.
Slotman BJ, Faivre-Finn C, van Tinteren H, Keijser A, Praag J, Knegjens J, Hatton M, van Dam I, van der Leest A, Reymen B, Stigt J, Haslett K, Tripathi D, Smit EF, Senan S.
Slotman BJ, et al. Among authors: knegjens j.
Lung Cancer. 2017 Jun;108:150-153. doi: 10.1016/j.lungcan.2017.03.007. Epub 2017 Mar 21.
Lung Cancer. 2017.
PMID: 28625628
Free article.